188RNL-BAM
Hepatocellular Carcinoma
Key Facts
About Plus Therapeutics
Plus Therapeutics is focused on developing targeted radiotherapeutics for rare and difficult-to-treat cancers, with a mission to deliver high-dose radiation precisely to tumors. The company's core innovation is a proprietary platform combining Rhenium isotopes, nanoliposomes, and biodegradable microspheres to enable localized, image-guided therapy. Key achievements include promising Phase 1 data for its lead candidate, REYOBIQ™, in recurrent glioblastoma and leptomeningeal metastases, and the advancement of a next-generation liver cancer program. Its strategy centers on advancing its clinical pipeline in high-unmet-need oncology indications while leveraging theranostic capabilities.
View full company profileAbout Plus Therapeutics
Plus Therapeutics is focused on developing targeted radiotherapeutics for rare and difficult-to-treat cancers, with a mission to deliver high-dose radiation precisely to tumors. The company's core innovation is a proprietary platform combining Rhenium isotopes, nanoliposomes, and biodegradable microspheres to enable localized, image-guided therapy. Key achievements include promising Phase 1 data for its lead candidate, REYOBIQ™, in recurrent glioblastoma and leptomeningeal metastases, and the advancement of a next-generation liver cancer program. Its strategy centers on advancing its clinical pipeline in high-unmet-need oncology indications while leveraging theranostic capabilities.
View full company profileTherapeutic Areas
Other Hepatocellular Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Namodenoson (CF102) | Can Fite Biopharma | Phase IIb/III |
| GC-101 | Genocury Biotech | Preclinical |
| DCR-MYC | Dicerna Pharmaceuticals | Preclinical |
| RYZ801 | RayzeBio | Preclinical |
| CT011 | CARsgen Therapeutics | Phase II |
| BRVT101 | Biorevert | Preclinical |
| BRVT121 | Biorevert | Phase I |
| BRVT151 | Biorevert | Phase I |
| HCC Diagnostic Test | Senseera | Clinical POC |
| RG6139 (RO7247669) | Chugai Pharmaceutical | Phase III |
| ALN-BCAT | Alnylam Pharmaceuticals | Phase 1 |
| HCC Program | Arcellx | Discovery |